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Acute Myeloid Leukaemia (AML) is frequently associated to normal karyotype and DNMT3A 
mutations (R882). Since we previously demonstrated distinctive miRNA expression in some 
AML groups, we study 384 miRNA in 9 selected DNMT3A-mutated NK-AML patients. 
Comparing these data with our previous results obtained in 31 DNMT3A-unmutated AML, we 
focused on a significant up-regulation of miR-155, miR-29a, miR-196b and miR-25. We 
investigated expression of these miRNAs in additional 24 DNMT3A-mutated AML patients and 
we confirm the up-regulation of miR-155, miR-29a and miR-196b; in particular, we judged very 
interesting the over expression of miR-29a since is known to directly target DNMT3A, TET1 and 
TDG mRNAs. Evaluating the expression levels of these targets in 17 AML DNMT3A-mutated 
patients, we revealed a no significant differences in expression of DNMT3A and TDG but a 
significant down-regulation of TET1. 
These data suggest that miR-29a acts as DNA methylation-regulator: in presence of DNMT3A 
activating mutations and TET1 down-regulation it may probably cause a perturbation of DNA 
methylation.  In fact, analyzing the methylation of the bone marrow genomic DNA from 3 
DNMT3A-mutated and 3 DNMT3A-unmutated cases by Methylation Sensitive Arbitrarily 
Primed-PCR, we found a genomic hypermethylation of DNMT3A-mutated cells compared to the 
unmutated ones. 
How DNMT3A mutations contribute to leukemogenesis is not yet well characterized. Uncovering 
how DNMT3A mutations affect DNA methylation and epigenetic regulation of gene expression 
may have important implications in treatment selection because DNA hypomethylating agents 
are increasingly used in AML therapies, and response to these drugs may be affected by 
DNMT3A changed function. 
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